A Study Assessing Fluorestradiol PET/CT for Imaging Estrogen Receptor Status

Full Title

Fluoroestradiol (FES) PET/CT for Imaging Estrogen Receptor Status

Purpose

Many breast and gynecologic cancers are fueled by estrogen, and those that are can be treated with drugs that target estrogen receptors. In this study, researchers are evaluating a new tool to measure the amount of estrogen receptors on a tumor — information which could help guide therapy. The tool is called fluorestradiol (FES) positron emission tomography/computed tomography (PET/CT).

FES finds estrogen receptors and binds to them. When FES is attached to radioactive fluorine, PET/CT can show where the FES is in the body and how much is present. The results of this study may help researchers learn if FES can be used to monitor changes in estrogen receptors in estrogen-sensitive cancers during treatment.

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have an estrogen receptor-positive cancer that will be treated with a therapy where estrogen receptors play an important role.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Gary Ulaner at 212-639-3776.

Protocol

13-071

Phase

0

Disease Status

Newly Diagnosed & Relapsed/Refractory

Investigator

Co-Investigators

Locations